Zhang Li, Hong Yuxiao, Zheng Song, Huo Wei, Qi Ruiqun, Geng Long, Chen Hong-Duo, Gao Xing-Hua
Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, China.
Dermatol Ther. 2014 Jul-Aug;27(4):240-3. doi: 10.1111/dth.12127. Epub 2014 Apr 22.
We previously reported a large Chinese pedigree of erythrokeratodermia variabilis (EKV). A unique feature was that some of the affected members experienced transitory pustules on the border of classic lesions. Here we prescribed oral arotinoid ethylester and acitretin to two of the affected members in the pedigree, at starting dosage of 0.03 mg/day for arotinoid ethylester and 30 mg/day for acitretin, maintenance dosage of 0.03 mg every other day and 20 mg/day, respectively. Both patients reached complete clearance of the lesions during the treatment period. Side effect was negligible for the case on arotinoid ethylester. The patient on acitretin experienced elevated level of serum triglyceride and alanine aminotransferase that restrained further use.
我们之前报道过一个大的变异性红斑角皮症（EKV）中国家系。一个独特的特征是，一些受影响的成员在经典皮损边界处出现过短暂脓疱。在此，我们给该家系中的两名受影响成员开了口服阿维A乙酯和阿维A，阿维A乙酯起始剂量为0.03毫克/天，阿维A为30毫克/天，维持剂量分别为每隔一天0.03毫克和20毫克/天。两名患者在治疗期间皮损均完全消退。阿维A乙酯治疗的患者副作用可忽略不计。服用阿维A的患者血清甘油三酯和谷丙转氨酶水平升高，限制了进一步用药。
